Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ibandronate

M Dooley1, J A Balfour

  • 1Adis International Limited, Mairangi Bay, Auckland, New Zealand. demail@adis.co.nz

Drugs
|February 10, 1999
PubMed
Summary
This summary is machine-generated.

Ibandronate, a potent bisphosphonate, effectively reduces bone resorption and normalizes calcium levels in cancer patients. It also improves bone mineral density in postmenopausal women with osteoporosis.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical Challenges of Tacrolimus for Maintenance Immunosuppression Post-Lung Transplantation.

Transplantation proceedings·2017
Same author

Morphological appearance of uterine cavity on ultrasound prior to development of intrauterine adhesions.

Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology·2017
Same author

Timely initiation of chemotherapy: a systematic literature review of six priority cancers - results and recommendations for clinical practice.

Internal medicine journal·2016
Same author

The impact of the introduction of an acute sedation practice guideline.

Acta neuropsychiatrica·2016
Same author

Sport, exercise and the menstrual cycle: where is the research?

British journal of sports medicine·2016
Same author

Cardiovascular events prior to or early after diagnosis of systemic lupus erythematosus in the systemic lupus international collaborating clinics cohort.

Lupus science & medicine·2016
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
See all related articles

Area of Science:

  • Pharmacology
  • Bone Metabolism
  • Oncology

Background:

  • Ibandronate is a third-generation bisphosphonate.
  • It inhibits bone resorption and, at high doses, bone formation.
  • It demonstrates greater potency than other bisphosphonates in preclinical models.

Purpose of the Study:

  • To evaluate the efficacy of ibandronate in managing hypercalcemia of malignancy.
  • To assess ibandronate's effects on bone mineral density and turnover in postmenopausal women.
  • To investigate ibandronate's potential in Paget's disease.

Main Methods:

  • Clinical studies involving intravenous and oral administration of ibandronate.
  • Dose-ranging studies in patients with hypercalcemia and osteoporosis.
  • Biochemical marker analysis (serum calcium, urinary markers, alkaline phosphatase) and bone mineral density measurements.

Related Experiment Videos

Main Results:

  • Single ibandronate doses normalized serum calcium in 50-76% of hypercalcemic cancer patients.
  • Ibandronate dose-dependently increased bone mineral density and reduced bone turnover markers in postmenopausal women.
  • A single dose reduced biochemical markers in Paget's disease patients.

Conclusions:

  • Ibandronate is effective in treating hypercalcemia of malignancy and improving bone health in osteoporosis.
  • Its potency and dose-dependent effects support its therapeutic use.
  • Adverse events include transient fever, hypocalcemia, hypophosphatemia, and gastrointestinal issues.